MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre review To guage various intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Major trial objectives ended up To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis clients, when one of many exploratory https://helenb222ozj4.wiki-promo.com/user